top of page
Subscriber login:
SUBMIT
Remember me
Search
How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
Nov 18, 2021
Express Scripts Coverage, FDA Label Update Boost Rybelsus
There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.
Jan 23, 2020
bottom of page